Clinical trials of mTOR inhibitors for treating AMLs, lymphangioleiomyomatosis, and subependymal giant cell astrocytomas are actively being undertaken [39]–[44]. This evidence concerns the gene MTOR and subependymal giant cell astrocytoma.